Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)
China · Delayed Price · Currency is CNY 5.83
+0.23 (4.11%)
At close: Aug 4, 2026
SHA:688238 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 265.39 | 267.7 | 248.15 | 204.81 | 291.3 | 254.95 |
Revenue Growth | 9.93% | 7.88% | 21.16% | -29.69% | 14.26% | 78.57% |
Gross Profit Gross Profit Growth | -34.96 | -42.16 | -102.92 | -16.93 | 129.37 | 130.88 |
Operating Income Operating Income Growth | -213.4 | -218.62 | -279.92 | -166.48 | 5.34 | 38.25 |
Net Income Net Income Growth | -228.67 | -235.06 | -321.81 | -127.94 | 39.26 | 54.26 |
Earnings Per Share EPS Growth | -0.36 | -0.37 | -0.50 | -0.20 | 0.07 | 0.11 |
EPS Growth | - | - | - | - | -38.80% | -56.86% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Gene Therapy CRO Service Gene Therapy CRO Service Growth | 93.23 |
Gene Therapy CDMO Service Gene Therapy CDMO Service Growth | 135.64 |
Regenerative Medicine Services Regenerative Medicine Services Growth | 3.85 |
Biological Agents, Reagents and Others Biological Agents, Reagents and Others Growth | 34.7 |
Total Total Growth | 267.41 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 200.96 | 292.59 | 469.7 | 657.05 | 1,254 | 619.01 |
Total Debt Total Debt Growth | 416.95 | 420.44 | 215.44 | 191.13 | 92 | 165.34 |
Net Cash (Debt) Net Cash Growth | -216 | -127.85 | 254.27 | 465.92 | 1,162 | 453.67 |
Net Cash Growth | - | - | -45.43% | -59.90% | 156.10% | -33.82% |
Net Cash Per Share Net Cash Per Share Growth | -0.34 | -0.20 | 0.39 | 0.72 | 1.92 | 0.89 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -107.25 | -102.59 | -61.07 | -90.12 | 21.42 | 109.31 |
Capital Expenditures CapEx Growth | -86.66 | -126.24 | -167.46 | -547.12 | -484.42 | -262.11 |
Free Cash Flow Free Cash Flow Growth | -193.92 | -228.84 | -228.53 | -637.24 | -462.99 | -152.8 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -13.17% | -15.75% | -41.47% | -8.27% | 44.41% | 51.34% |
Operating Margin | -80.41% | -81.67% | -112.80% | -81.29% | 1.83% | 15.00% |
Pretax Margin | -85.47% | -87.07% | -125.98% | -75.98% | 14.29% | 23.84% |
Profit Margin | -86.16% | -87.81% | -129.69% | -62.47% | 13.48% | 21.28% |
FCF Margin | -73.07% | -85.48% | -92.09% | -311.15% | -158.94% | -59.94% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 239.46 | - |
Forward PE | - | 132.36 | 132.36 | 137.88 | 81.09 | - |
PS Ratio | 13.85 | 15.68 | 12.92 | 28.42 | 32.27 | - |